ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2026
[Chinese expert consensus on infection management in multiple myeloma patients treated with bispecific antibody (2026)].
Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bispecific antibody (BsAb) is a novel immunotherapy for relapsed/refractory multiple myeloma (MM), which induces tumor cell killing by bridging T cells with tumor surface antigens and has significantly prolonged patient survival. However, the unique immune activation mechanism of BsAb leads to sustained T-cell activation, B-cell depletion, and hypogammaglobulinemia, markedly increasing infection risk in patients. The overall incidence of infection is 45.8% -80%, becoming a critical issue affecting treatment safety. With the widespread application of BsAb in China, understanding of related infections has been continuously deepened, and infection monitoring techniques, prevention protocols, and treatment strategies are also being optimized. To standardize the prevention and control of BsAb-related infections in MM patients in China, the Plasma Cell Disease Group, Chinese Society of Hematology, Chinese Medical Association and Chinese Myeloma Committee-Chinese Hematology Association have developed this consensus based on the latest evidence. This consensus mainly applies to the infection monitoring, prevention, and management during the treatment of BsAb in MM patients, aiming to enhance the recognition and management capability of infection-related complications and enable patients to achieve optimal progression-free survival and overall survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.